Related Experiment Video
Updated: Jul 30, 2026
11:20
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
[Azithromycin therapy in cystic fibrosis]
Luis Máiz Carro1, Rafael Cantón Moreno
1Unidad de Fibrosis Quística, Servicio de Neumología, Hospital Ramón y Cajal, Madrid, Spain. lmaiz.hrc@salud.madrid.org
Medicina Clinica
|March 20, 2004
Summary
Azithromycin (AZM) offers safe and effective treatment for cystic fibrosis (CF) patients, reducing pulmonary exacerbations and improving lung function. Chronic AZM therapy should be considered as an adjunct to standard CF care.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Pharmacology
Context:
- Cystic Fibrosis (CF) is characterized by progressive lung disease due to chronic bacterial infections.
- Staphylococcus aureus and Pseudomonas aeruginosa are key pathogens contributing to CF lung disease morbidity and mortality.
- Antibiotic therapy targeting these pathogens has improved CF patient prognosis.
Purpose:
- To evaluate the efficacy and safety of azithromycin (AZM) as a chronic treatment for cystic fibrosis patients.
- To explore the potential anti-inflammatory and anti-virulence mechanisms of macrolide antibiotics in CF.
Summary:
- Limited clinical trials suggest that 3 to 6-month azithromycin (AZM) treatment is safe and well-tolerated in CF patients.
- AZM treatment leads to clinical improvements, including reduced pulmonary exacerbations and enhanced lung function.
- Evidence supports considering chronic AZM as an add-on therapy to conventional CF treatment regimens.
Impact:
- Azithromycin (AZM) demonstrates potential as a valuable therapeutic option for managing chronic lung disease in cystic fibrosis.
- Findings support the integration of chronic macrolide therapy into standard CF care protocols.
- Further research into macrolide mechanisms of action in CF is warranted.
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:24Chest Physiotherapy
Chest Physiotherapy (CPT) is a therapeutic technique used in respiratory care to improve ventilation, clear bronchial secretions, and enhance the efficiency of respiratory muscles. This therapy includes three primary procedures: postural drainage, percussion, and vibration. It can be performed on spontaneously breathing patients and those who are intubated and mechanically ventilated.
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...